Bing Lu

562 total citations
13 papers, 360 citations indexed

About

Bing Lu is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Bing Lu has authored 13 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 4 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Bing Lu's work include SARS-CoV-2 and COVID-19 Research (4 papers), HIV Research and Treatment (4 papers) and HIV/AIDS drug development and treatment (4 papers). Bing Lu is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), HIV Research and Treatment (4 papers) and HIV/AIDS drug development and treatment (4 papers). Bing Lu collaborates with scholars based in China, United States and United Kingdom. Bing Lu's co-authors include Rosa I. Sánchez, Yuan Shen, Kerry L. Fillgrove, Qiang Wang, Liuqing Yang, Tingting Cui, Daniel Skomski, Naiyang Shi, Stephanie E. Barrett and Sandra L. Wood and has published in prestigious journals such as The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and Emerging infectious diseases.

In The Last Decade

Bing Lu

12 papers receiving 358 citations

Peers

Countries citing papers authored by Bing Lu

Since Specialization

Citations

This map shows the geographic impact of Bing Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Lu more than expected).

Fields of papers citing papers by Bing Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bing Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Lu. The network helps show where Bing Lu may publish in the future.

Co-authorship network of co-authors of Bing Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Bing Lu. A scholar is included among the top collaborators of Bing Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bing Lu. Bing Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Infection Rates and Symptomatic Proportion of SARS-CoV-2 and Influenza in Pediatric Population, China, 2023 2024 ·Emerging infectious diseases ·(unknown), Yuhe Zhang, Sheng Ye, Jiyang Zhou, (unknown), Yumeng Gao, Yan Wang, Bingbing Cong, (unknown), You Li, Bing Lu, Xin Wang	0
2	Respiratory Pathogen Coinfection During Intersecting COVID-19 and Influenza Epidemics 2024 ·Pathogens ·Lina Jiang, Yifei Jin, Jingjing Li, (unknown), (unknown), (unknown), Bing Lu, (unknown), (unknown), Zhongyi Wang	1
3	Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent 2023 ·Molecular Pharmaceutics ·Raju Subramanian, Jennifer Tang, Jim Zheng, Bing Lu, Kelly Wang, Stephen R. Yant, George Stepan, Andrew Mulato, Helen Yu, Scott D. Schroeder, M. Naveed Shaik, (unknown), Scott A. Wolckenhauer, Anne Chester, Winston C. Tse, Anna Chiu, Martin S. Rhee, Tomáš Cihlář, William Rowe, Bill J. Smith	27
4	Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection 2021 ·The Journal of Infectious Diseases ·Yao Lin, Guolin Wang, Yuan Shen, (unknown), (unknown), Li‐Jun Duan, Bing Lu, Chao Shi, Yumeng Gao, (unknown), Guoqiang Wang, Dongmei Wang, (unknown), (unknown), Mai‐Juan Ma	43
5	Vaccine Hesitancy: COVID-19 and Influenza Vaccine Willingness among Parents in Wuxi, China—A Cross-Sectional Study 2021 ·Vaccines ·Qiang Wang, (unknown), (unknown), Jianli Wang, (unknown), (unknown), (unknown), Tingting Cui, Liuqing Yang, Naiyang Shi, (unknown), Yue Han, (unknown), Yuan Shen, (unknown), Bing Lu, Hui Jin, Leesa Lin	86
6	Delays in routine childhood vaccinations and their relationship with parental vaccine hesitancy: a cross-sectional study in Wuxi, China 2021 ·Expert Review of Vaccines ·Qiang Wang, (unknown), Liuqing Yang, (unknown), (unknown), Tingting Cui, Naiyang Shi, (unknown), (unknown), Bing Lu, Hui Jin, Leesa Lin	14
7	A Novel Strategy for the Detection of SARS-CoV-2 Variants Based on Multiplex PCR-Mass Spectrometry Minisequencing Technology 2021 ·Microbiology Spectrum ·Fei Zhao, Jinxing Lu, Bing Lu, Tian Qin, Xuemei Wang, Xuexin Hou, Fanliang Meng, (unknown), Tianyi Li, Haijian Zhou, Jianzhong Zhang, Biao Kan, Ying Huang, Zehui Zhang, Di Xiao	15
8	Characteristics and evaluation of the effectiveness of monitoring and control measures for the first 69 Patients with COVID-19 from 18 January 2020 to 2 March in Wuxi, China 2020 ·Sustainable Cities and Society ·(unknown), Yumeng Gao, Yuan Shen, Enping Chen, Hai Chen, (unknown), Yujun Chen, Yong Xiao, (unknown), Chao Shi, Bing Lu	9
9	Chronic exposure to microcystin-LR reduces thyroid hormone levels by activating p38/MAPK and MEK/ERK signal pathway 2019 ·Ecotoxicology and Environmental Safety ·(unknown), Rongwen Bian, Li Jiang, Liang Qiu, Bing Lu, (unknown)	23
10	In Vitro Evaluation of the Drug Interaction Potential of Doravirine 2019 ·Antimicrobial Agents and Chemotherapy ·Kelly Bleasby, Kerry L. Fillgrove, Robert Houle, Bing Lu, Jairam Palamanda, Deborah J. Newton, Meihong Lin, Grace Chan, Rosa I. Sánchez	23
11	Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention 2018 ·Antimicrobial Agents and Chemotherapy ·Stephanie E. Barrett, Ryan S. Teller, Seth Forster, Li Li, Megan Mackey, Daniel Skomski, (unknown), Kerry L. Fillgrove, (unknown), Sandra L. Wood, José Antonio Lebrón, Jay A. Grobler, Rosa I. Sánchez, (unknown), Bing Lu, Tao Niu, Li Sun, Marian E. Gindy	99
12	539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans 2018 ·Open Forum Infectious Diseases ·Jim Zheng, Stephen R. Yant, Shekeba Ahmadyar, (unknown), Anna Chiu, Tomáš Cihlář, John O. Link, Bing Lu, Judy Mwangi, William Rowe, Scott D. Schroeder, George Stepan, (unknown), Raju Subramanian, Winston C. Tse	12
13	LC–MS/MS determination and pharmacokinetic study of columbianadin in rat plasma after intravenous administration of pure columbianadin 2014 ·Chemistry Central Journal ·Yanxu Chang, Chunpeng Wang, Jin Li, Yang Bai, Qian Luo, Jun He, Bing Lu, (unknown), Boli Zhang, Xiumei Gao	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact